A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)

Cannot have received: antibody-drug conjugate with topoisomerase I inhibitor toxin

Previously received ADC drugs with topoisomerase I inhibitors as the toxin

Cannot have received: EGFR inhibitor

Previously received ADC drugs ... targeting EGFR

Cannot have received: HER3 inhibitor

Previously received ADC drugs ... targeting ... HER3

Cannot have received: chemotherapy

Exception: within 4 weeks or 5 half-lives (whichever is shorter) before the first dose

Received chemotherapy ... within 4 weeks or 5 half-lives (whichever is shorter) before the first dose

Cannot have received: biological therapy

Exception: within 4 weeks or 5 half-lives (whichever is shorter) before the first dose

Received ... biological therapy ... within 4 weeks or 5 half-lives (whichever is shorter) before the first dose

Cannot have received: immunotherapy

Exception: within 4 weeks or 5 half-lives (whichever is shorter) before the first dose

Received ... immunotherapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose

Cannot have received: systemic anti-tumor therapy

Exception: Stage II (excluding Cohort 1)

For Stage II (excluding Cohort 1), subjects who have previously received systemic anti-tumor therapy

Cannot have received: immunotherapy

Exception: resulting in ≥ Grade 3 irAE or ≥ Grade 2 immune-related myocarditis

Prior immunotherapy resulting in ≥ Grade 3 irAE or ≥ Grade 2 immune-related myocarditis